Yuka Kobayashi

Regulatory T cells exhibit differential therapeutic effects across tissues during chronic autoimmune inflammation.

Current therapies for autoimmune diseases rely largely on non-specific immunosuppression, which can lead to adverse effects such as malignancy and severe infections. Treg-based therapies have therefore attracted attention as a more targeted approach, particularly in preventive or early-stage settings. However, their ef...